Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study - Archive ouverte HAL
Article Dans Une Revue Journal of the American Heart Association Année : 2022

Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study

Kim Bouillon
  • Fonction : Auteur
Bérangère Baricault
  • Fonction : Auteur
Laura Semenzato
  • Fonction : Auteur
Jérémie Botton
Marion Bertrand
  • Fonction : Auteur
Jérôme Drouin
  • Fonction : Auteur
Rosemary Dray-Spira
Alain Weill
  • Fonction : Auteur

Résumé

BACKGROUND: There is little evidence on the relationship between statin use and the risk of hospitalization attributable to COVID-19. METHODS AND RESULTS: The French National Healthcare Data System database was used to conduct a matched-cohort study. For each adult aged ≥40 years receiving statins for the primary prevention of cardiovascular diseases, one nonuser was randomly selected and matched for year of birth, sex, residence area, and comorbidities. The association between statin use and hospitalization for COVID-19 was examined using conditional Cox proportional hazards models, adjusted for baseline characteristics, comorbidities, and long-term medications. Its association with in-hospital death from COVID-19 was also explored. All participants were followed up from February 15, 2020, to June 15, 2020. The matching procedure generated 2 058 249 adults in the statin group and 2 058 249 in the control group, composed of 46.6% of men with a mean age of 68.7 years. Statin users had a 16% lower risk of hospitalization for COVID-19 than nonusers (adjusted hazard ratio [HR], 0.84; 95% CI, 0.81–0.88). All types of statins were significantly associated with a lower risk of hospitalization, with the adjusted HR ranging from 0.75 for fluvastatin to 0.89 for atorvastatin. Low-and moderate-intensity statins also showed a lower risk compared with nonusers (HR, 0.78 [95% CI, 0.71–0.86] and HR, 0.84 [95% CI, 0.80–0.89], respectively), whereas high-intensity statins did not (HR, 1.01; 95% CI, 0.86–1.18). We found similar results with in-hospital death from COVID-19. CONCLUSIONS: Our findings support that the use of statins for primary prevention is associated with lower risks of hospitalization for COVID-19 and of in-hospital death from COVID-19.
Fichier principal
Vignette du fichier
JAHA.121.023357.pdf (888.05 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-03775093 , version 1 (06-06-2023)

Licence

Identifiants

Citer

Kim Bouillon, Bérangère Baricault, Laura Semenzato, Jérémie Botton, Marion Bertrand, et al.. Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study. Journal of the American Heart Association, 2022, 11 (12), ⟨10.1161/JAHA.121.023357⟩. ⟨hal-03775093⟩
27 Consultations
37 Téléchargements

Altmetric

Partager

More